Fate Therapeutics Past Earnings Performance
Past criteria checks 0/6
Fate Therapeutics's earnings have been declining at an average annual rate of -20.9%, while the Biotechs industry saw earnings growing at 14.5% annually. Revenues have been growing at an average rate of 47.4% per year.
Key information
-20.9%
Earnings growth rate
-12.4%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 47.4% |
Return on equity | -43.7% |
Net Margin | -253.3% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Fate Therapeutics, Inc. (NASDAQ:FATE) Held Back By Insufficient Growth Even After Shares Climb 57%
Feb 16Fate Therapeutics Update: A Rally Based On Little Increases Near-Term Risks
Jan 26Fate Therapeutics, Inc.'s (NASDAQ:FATE) Shares Bounce 30% But Its Business Still Trails The Industry
Dec 19Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Deliver On Growth Plans?
Sep 08Benign Growth For Fate Therapeutics, Inc. (NASDAQ:FATE) Underpins Its Share Price
Jun 07Industry Analysts Just Upgraded Their Fate Therapeutics, Inc. (NASDAQ:FATE) Revenue Forecasts By 41%
May 08Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Invest In Growth?
Apr 17We Think Fate Therapeutics (NASDAQ:FATE) Needs To Drive Business Growth Carefully
Jan 10Here's Why We're Not Too Worried About Fate Therapeutics' (NASDAQ:FATE) Cash Burn Situation
Sep 22Fate Therapeutics: Yes For Speculators, No For Defensive Investors
Aug 30Needham initiates Fate coverage Therapeutics on potential of stem cell therapies
Jul 28Fate Therapeutics names Brian Powl as chief commercial officer
Jun 30Fate: Possible Speedy FDA Approval Process With RMAT Designation
Jun 03We're Hopeful That Fate Therapeutics (NASDAQ:FATE) Will Use Its Cash Wisely
Jun 02Fate Therapeutics: Slowly Getting To An Attractive Position
Feb 21We're Not Very Worried About Fate Therapeutics' (NASDAQ:FATE) Cash Burn Rate
Feb 01Fate Therapeutics: Data Playing Catchup With Valuation
Dec 06Fate Therapeutics (NASDAQ:FATE) Is In A Good Position To Deliver On Growth Plans
Oct 16Fate Therapeutics: We Will Wait For Durability Data
Sep 16Revenue & Expenses BreakdownBeta
How Fate Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 64 | -161 | 79 | 0 |
30 Sep 23 | 106 | -173 | 85 | 0 |
30 Jun 23 | 119 | -212 | 88 | 0 |
31 Mar 23 | 137 | -235 | 83 | 0 |
31 Dec 22 | 96 | -282 | 84 | 0 |
30 Sep 22 | 69 | -294 | 80 | 0 |
30 Jun 22 | 68 | -254 | 74 | 0 |
31 Mar 22 | 63 | -233 | 66 | 0 |
31 Dec 21 | 56 | -212 | 57 | 0 |
30 Sep 21 | 55 | -197 | 51 | 0 |
30 Jun 21 | 48 | -212 | 43 | 0 |
31 Mar 21 | 40 | -185 | 39 | 0 |
31 Dec 20 | 31 | -173 | 34 | 0 |
30 Sep 20 | 18 | -149 | 30 | 0 |
30 Jun 20 | 13 | -117 | 28 | 0 |
31 Mar 20 | 11 | -112 | 26 | 0 |
31 Dec 19 | 11 | -98 | 24 | 0 |
30 Sep 19 | 10 | -86 | 21 | 0 |
30 Jun 19 | 8 | -76 | 19 | 0 |
31 Mar 19 | 6 | -72 | 18 | 0 |
31 Dec 18 | 5 | -67 | 16 | 0 |
30 Sep 18 | 4 | -63 | 15 | 0 |
30 Jun 18 | 4 | -57 | 14 | 0 |
31 Mar 18 | 4 | -47 | 12 | 0 |
31 Dec 17 | 4 | -43 | 12 | 0 |
30 Sep 17 | 4 | -38 | 11 | 0 |
30 Jun 17 | 4 | -36 | 11 | 0 |
31 Mar 17 | 4 | -35 | 10 | 0 |
31 Dec 16 | 4 | -33 | 10 | 0 |
30 Sep 16 | 4 | -33 | 10 | 0 |
30 Jun 16 | 4 | -31 | 10 | 0 |
31 Mar 16 | 4 | -30 | 10 | 0 |
31 Dec 15 | 2 | -30 | 10 | 0 |
30 Sep 15 | 1 | -29 | 10 | 0 |
30 Jun 15 | 0 | -28 | 9 | 0 |
31 Mar 15 | 0 | -27 | 9 | 0 |
31 Dec 14 | 0 | -26 | 8 | 0 |
30 Sep 14 | 0 | -25 | 8 | 0 |
30 Jun 14 | 0 | -25 | 8 | 0 |
31 Mar 14 | 0 | -24 | 8 | 0 |
31 Dec 13 | 1 | -21 | 7 | 0 |
30 Sep 13 | 2 | -19 | 6 | 0 |
30 Jun 13 | 2 | -17 | 5 | 0 |
31 Mar 13 | 3 | -15 | 4 | 0 |
Quality Earnings: FATE is currently unprofitable.
Growing Profit Margin: FATE is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: FATE is unprofitable, and losses have increased over the past 5 years at a rate of 20.9% per year.
Accelerating Growth: Unable to compare FATE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: FATE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: FATE has a negative Return on Equity (-43.68%), as it is currently unprofitable.